Short sellers are piling into KYTX ahead of May earnings. The lending market tells a conflicting story — and that contradiction is worth watching.
Short interest in Kyverna Therapeutics hit 11.9% of free float as of May 12. That's up 22% week-on-week and 24.7% month-on-month — one of the sharpest buildups in the stock's recent history.
The surge coincided with a 10.6% single-session rally on May 12. Bears added to positions even as the stock ripped higher. That's an aggressive move.
The ORTEX short score climbed to 75 on May 11, up from 71.5 just two weeks prior. Scores above 70 indicate elevated short-selling pressure relative to the stock's own history and peers.
Here's the contradiction: availability has tightened sharply, yet the cost to borrow collapsed.
The lending pool has been almost fully tapped for weeks. The pool hit its 52-week tightest on multiple occasions — most recently May 11, when every share available was lent out. As of May 12, availability had eased slightly but remained extremely tight. With borrowing demand this high, fresh short positions are difficult to establish.
Yet the cost to borrow fell 84.5% in one week to just 0.19% annualised. A month ago it stood at roughly 0.74%. That drop is unusual when availability is this constrained. It likely reflects a shift in lender composition or a batch of cheaper shares entering the pool — not a relaxation of overall demand.
The two signals don't cancel each other out. Tight availability remains the dominant read on the lending market. The CTB drop is a data point to track, not a conclusion.
Kyverna reports on May 27. Prior earnings moves have been volatile. The stock fell 7.4% the day after the November 2025 print, then recovered 17.6% over the following five days. The April 2026 event produced a 4.6% gain on the day and a 25.7% five-day move.
Options markets are tilting cautious. The put/call ratio stood at 0.29 on May 12 — a one-standard-deviation move above the 20-day mean of 0.21. That's not extreme, but it's the highest reading in recent weeks and is trending up.
Analysts remain constructive. The consensus mean price target is $29.40 against a current price of $10.23. Wells Fargo and Morgan Stanley both carry Overweight ratings with targets of $33 and $25 respectively. The bull case centres on KYV-101's efficacy data across multiple autoimmune indications.
See the live data behind this article on ORTEX.
Open KYTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
